How it works: Ibrutinib blocks Bruton’s tyrosine kinase (BTK), disrupting survival and proliferation signalling in malignant B-lymphocytes. This inhibits tumour growth and disease progression.
Who it’s for:
– Patients with Chronic Lymphocytic Leukaemia (CLL)
– Individuals with Mantle Cell Lymphoma (MCL), especially in relapse
– Those with Waldenström’s Macroglobulinemia (WM)
– Patients seeking oral, targeted treatment with low toxicity
– Chronic Lymphocytic Leukaemia (CLL)
– Mantle Cell Lymphoma (MCL)
– Waldenström’s Macroglobulinemia (WM)
– Marginal Zone Lymphoma (in selected regimens)
Ibrutinib is taken orally, typically once daily at 420–560 mg depending on diagnosis and treatment plan. Tablets should be swallowed whole with water, with or without food. Dosage and duration are determined by the treating physician.
Contraindicated in patients with hypersensitivity to ibrutinib, active infections, or severe liver impairment. Possible side effects include bleeding, diarrhoea, high blood pressure, dizziness, and infections. Medical supervision and regular blood tests are essential.
